Guselkumab
Interleukin Inhibitors
Sold as TREMFYA · TREMFYA I.V. · TREMFYA ONE-PRESS
- Drug class
- Interleukin Inhibitors
- Availability
- See label
- Routes
- Subcutaneous, Intravenous
- Markets covered
- 3
- Products on record
- 14
Overview
Guselkumab is an active pharmaceutical ingredient in the Interleukin Inhibitors group (L04AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 7 | May 22, 2026 |
| EU European Union | EMA | 1 | March 23, 2026 |
| CA Canada | Health Canada | 6 | May 14, 2026 |
GBUnited Kingdom· MHRA
7 products
Uses
Crohn’s disease Tremfya is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.
Ulcerative colitis Tremfya is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.
How to take
EUEuropean Union· EMA
1 product
Uses
Paediatric plaque psoriasis Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.
How to take
CACanada· Health Canada
6 products
6 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (3)
Drug interactions
Known interactions involving Guselkumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL002420767 · revised March 6, 2026
- [2]European Medicines Agency · EMEA/H/C/004271 · revised March 23, 2026
- [3]Health Canada (DPD) · 02469758 · revised April 17, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.